Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Diabetes Tech Pionee | Insulet's Omnipod 5 AID system, now FDA-cleared for both Type 1 and Type 2 diabetes, opens new growth avenues in the vast, underpenetrated insulin pump market |
Financial Momentum | Strong Q2 2024 results exceed expectations, with total revenue up 27% YoY to $488 million, prompting raised FY2024 guidance to 18%-21% growth |
Market Expansion Potential | Explore how Omnipod 5's entry into Type 2 diabetes market, with 6 million potential new customers, could drive substantial long-term revenue growth |
Analyst Perspectives | Price targets range from $200 to $236, with Canaccord Genuity maintaining a BUY rating, reflecting optimism about Insulet's market position and growth prospects |
Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
---|---|---|---|---|
P/E Ratio | 41.9x | −10.6x | −0.6x | |
PEG Ratio | 0.08 | −0.05 | 0.00 | |
Price/Book | 16.6x | 2.6x | 2.6x | |
Price / LTM Sales | 8.9x | 3.5x | 3.2x | |
Upside (Analyst Target) | 6.1% | 52.5% | 48.6% | |
Fair Value Upside | Unlock | −0.1% | 7.0% | Unlock |